Evidence map›Paper›PMID 40402450›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

NKT Hybridoma Cell Stimulation Assays to Evaluate Glycolipid Specificity and Processing.

Kumiko Nishio, Kevin S Hsu, Jay A Berzofsky, Purevdorj B Olkhanud

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kumiko Nishio *Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Kevin S Hsu *Vaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Jay A BerzofskyVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.
Purevdorj B OlkhanudVaccine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA. purevdorj.olkhanud@nih.gov.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural Killer T (NKT) cells, a specialized subset of T cells, play a pivotal role in immune surveillance. They recognize lipid antigens presented by the MHC class I-like molecule CD1d, bridging innate and adaptive immunity. NKT cells exhibit both pro-inflammatory and immunoregulatory properties, impacting various pathological states, including infections, autoimmune diseases, and cancer. The NKT hybridoma cell stimulation assay is a powerful tool for detecting and characterizing NKT cells, as well as screening natural and synthetic lipid antigens, potentially leading to novel therapeutic interventions. Here, we describe two complementary methods (cell-free and cell-based) to stimulate NKT hybridoma cells to secrete cytokine, which serves as an indirect measure of NKT cell activation. These assays provide insight into the intricate interplay between NKT cells, lipids, and other immune cell subsets, including antigen-presenting cells, and their impact on immune regulation and disease progression.

Indexed as

GlycolipidsHybridomasLymphocyte ActivationNatural Killer T-CellsAnimalsAntigen PresentationAntigens, CD1dCytokinesHumansMiceAntigens, CD1dCytokinesGlycolipidsGlycolipid-loaded mCD1d monomerGlycolipid processingLipid antigen processing and presentation by antigen-presenting cellsNKT cellsNKT hybridoma cell stimulation

Identifiers

PMID40402450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.